Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Alternative cellular therapies for patients with CLL

Peter Hillmen, MBChB, FRCP, FRCPath, PhD, University of Leeds, Leeds, UK, shares some insights into cellular therapy for chronic lymphocytic leukemia (CLL), drawing focus to patients who have not responded to either Bruton’s tyrosine kinase (BTK) inhibitors or BCL2 inhibitors. Dr Hillmen mentions the challenge associated with getting CAR-T therapy for these patients, as well as the benefit of these emerging treatment options, including lisocabtagene maraleucel, ibrutinib, and allogeneic transplant. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.